Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
B.P. Kearney, J.F. Flaherty, J. Shah.
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
Clin Pharmacokinet, 43 (2004), pp. 595-612
[2.]
B.P. Kearney, K. Yale, J. Shah, L. Zhong, J.F. Flaherty.
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Clin Pharmacokinet, 45 (2006), pp. 1115-1124
[3.]
A. Pruvost, E. Negredo, H. Benech, F. Theodoro, J. Puig, E. Grau, et al.
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virusinfected patients.
Antimicrob Agents Chemother, 49 (2005), pp. 1907-1914
[4.]
C. Torti, E. Quirós-Roldon, M. Regazzi, A. Antinoni, A. Patroni, P. Villani, Collaboration Group of the MASTER Cohort, et al.
Early virological failure alter tenofovir + didanosine + efafirenz combination in HIV-positive patients upon starting antirretroviral therapy.
Antiviral Therapy, 10 (2005), pp. 505-513
[5.]
J.E. Gallant, S. Staszewski, A.L. Pozniak, E. DeJesus, J.M.A.H. Suleiman, M.D. Miller, et al.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial.
JAMA, 292 (2004), pp. 191-201
[6.]
A.L. Pozniak, J.E. Gallant, S. Staszewski, J.M. Suleiman, E. DeJesus, B. Lu, et al.
Similar 96-week efficacy profile regardless of baseline characteristic variable for tenofovir disoproxil fumarate (tdf) versus stavudine (d4t) when used in combination with lamivudine and efavirenz in antiretroviral naive patients.
Antivir Ther, 8 (2003),
[7.]
A.L. Pozniak, J.E. Gallant, E. DeJesus, J.R. Arribas, B. Gazzard, R.E. Campo, et al.
Tenofocir disoproxil fumarate, emtricitabine, and efavirenz versus fixed dose zidovudine/lamivudine and efavirenz in antirretroviral-naive patients. Virologic, immunologic, and morphologic changes: a 96-week analysis.
J Acquir Immune Defic Syndr, 43 (2006), pp. 535-540
[8.]
J.R. Arribas, A.L. Pozniak, J.E. Gallant, E. DeJesus, B. Gazzard, R.E. Campo, et al.
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
J Acquir Immune Defic Syndr, 47 (2008), pp. 74-78
[9.]
E. Martínez, A. Mocroft, M.A. García-Viejo, J.B. Pérez Cuevas, J.L. Blanco, Mallolas, et al.
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Lancet, 357 (2001), pp. 592-598
[10.]
J.E. Gallant, E. DeJesus, J.R. Arribas, A.L. Pozniak, B. Gazzard, R.E. Campo, et al.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med, 354 (2006), pp. 251-260
[11.]
E. Martínez, J.A. Arranz, D. Podzamczer, E. Ribera, V. Roca, et al.
Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention,
[12.]
J.M. Whitcomb, N. Parkin, C. Chappey, N.S. Hellman, C.J. Petropoulos.
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
J Infect Dis, 188 (2003), pp. 992-1000
[13.]
E. Svarovskaia, N. Margot, A. Bae, J. Waters, D. Goodman, L. Zhong, et al.
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
J AIDS, 46 (2007), pp. 174-180
[14.]
M. Sulkowski, S. Mehta, M. Torbenson, Y. Higgins, S. Brinkley, R. de Oca, et al.
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
AIDS, 21 (2007), pp. 2209-2216
[15.]
M. Sulkowski, D. Thomas, R. Chaisson, R. Moore.
Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection.
JAMA, 283 (2000), pp. 74-80
[16.]
F. Bani-Sadr, L. Denoeud, P. Morand, F. Lunel-Fabiani, S. Pol, P. Cacoub, et al.
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?.
J Acquir Immune Defic Syndr, 45 (2007), pp. 123-125
[17.]
S.W. Sabin, R. Weber, W. El-Sadr, P. Reiss, P. Thiebaut, S. DeWit, The DAD Study Group, et al.
Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The DAD Study.
15th Conference on Retroviruses and Opportunistic Infections,
[18.]
I. Diseases NIoAa.
NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC/3TC Found Less Effective in Subgroup of Antiretroviral-Naïve Individuals.
Health NIo, editor, (2008),
[19.]
M.R. Nelson, C. Katlama, J.S. Montaner, D.A. Cooper, B. Gazzard, B. Clotet, et al.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS, 21 (2007), pp. 1273-1281
[20.]
J.E. Gallant, M.A. Parish, J.C. Keruly, R.Dl. Moore.
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Clin Infect Dis, 40 (2005), pp. 1194-1198
[21.]
S.K. Gupta.
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
AIDS Patient care STDS, 22 (2008), pp. 99-103
[22.]
A.E. Zimmermann, T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman, G. Braden.
Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions.
Clin Infect Dis, 42 (2006), pp. 283-290
[23.]
J. Roling, H. Schmid, M. Fischereder, R. Draenert, F.D. Goebel.
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
Clin Infect Dis, 42 (2006), pp. 1488-1495
[24.]
European AIDS Clinical Society (EACS). Guidelines on the prevention and management of metabolic diseases in HIV (accedido, 12 Abr 2008). Disponible en: www.eacs.eu/guide/index.htm
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
